

JAN 25 2007

REMARKS

This Amendment filed in response to the Office Action dated July 27, 2006, accompanied by an extension of time for 3 additional months is timely filed within the 6 month time period for response, which time period is set to expire on January 29, 2006 because January 27, 2006 falls on a date that the United States Patent and Trademark Office is closed. Reconsideration of this application is requested in view of the foregoing amendments and the following remarks.

Amendments

Before this amendment, claims 1-20 were pending. Claims 9 and 10 have been cancelled. Claims 1 and 16-17 have been amended in this amendment. Thus, with entry of this amendment, claims 1-8 and 11-20 as amended are presently pending in the application.

Support for the amendment to claims 1, 16 and 17 are found in previously pending claims 1, 16 and 17. Further amendment to claims 1, 16 and 17 were found in claims 9 and 10 as originally pending.

Rejection Under 35 USC 102

Claims 1-8, 11-14, and 16-20 were rejected under 35 USC 102, as purportedly being anticipated by U.S. Patent No. 6,063,745 (Graham). The difference between Graham and the present invention is that Graham does not teach a composition containing polyether and a cationic polysaccharide. Graham does not teach inhibiting adhesion of bacteria to a biomedical device or contact lens. Graham does not teach each and every element of claims 1, 16 and 17 and any claims that depend from these claims.

Claims 1-8, 11-20 were rejected under 35 USC 102, as purportedly being anticipated by U.S. Patent No. 5,604,189 (Zhang). The difference between Zhang and the present invention is that Zhang does not teach a composition containing polyether and a cationic polysaccharide. Zhang does not teach inhibiting adhesion of bacteria to a biomedical device or contact lens. Zhang does not teach each and every element of claims 1, 16 and 17 and any claims that depend from these claims.


Claims 1-13, and 16-20 were rejected under 35 USC 102, as purportedly being anticipated by U.S. Patent No. 6,228,323 (Asgharian). The difference between Asgharian and the present invention is that Asgharian does not teach a composition containing polyether and a cationic polysaccharide. Polyquaternium-1 is not a cationic polysaccharide. Asgharian additionally does not teach inhibiting adhesion of bacteria to a biomedical device or contact lens. Asgharian does not teach each and every element of claims 1, 16 and 17 and any claims that depend from these claims.

Claims 1-8, 11-14 and 16-20 were rejected under 35 USC 102, as purportedly being anticipated by U.S. Patent No. 6,207,628 (Soyer). The difference between Soyer and the present invention is that Soyer does not teach a composition containing polyether and a cationic polysaccharide. Soyer does not teach inhibiting adhesion of bacteria to a biomedical device or contact lens. Soyer does not teach each and every element of claims 1, 16 and 17 and any claims that depend from these claims.

In view of the foregoing arguments and amendments, Applicants believe that the application is in condition for allowance. An early and favorable action on the merits is solicited.

Respectfully submitted,

Dated: January 25, 2007


Paul T. Lavoie
Attorney for Applicants
Registration No. 38,681

BAUSCH & LOMB INCORPORATED
One Bausch & Lomb Place
Rochester, NY 14604-2701
Telephone: (585) 338-6353
Facsimile: (585) 338-8706
Email: Paul.T.Lavoie@bausch.com